JNJ
Johnson & Johnson
Stock NYSE – Stock Market Prices, News & Analysis
Johnson & Johnson is an American healthcare group, founded in 1886 and based in New Brunswick, operating mainly in two segments: innovative pharmaceuticals and medical devices ("MedTech"). J&J regularly appears in innovation rankings for its ability to develop cutting-edge treatments in areas such as oncology, cardiology, and surgical technologies.
Johnson & Johnson
JNJ
Johnson & Johnson is an American healthcare group, founded in 1886 and based in New Brunswick, operating mainly in two segments: innovative pharmaceuticals and medical devices ("MedTech"). J&J regularly appears in innovation rankings for its ability to develop cutting-edge treatments in areas such as oncology, cardiology, and surgical technologies.
Anantys Community
Anantys Community
1 member holds Johnson & Johnson with an average return of 53.1%. Join them to follow signals and build your long-term investment strategy.
Price history of Johnson & Johnson
Price history of Johnson & Johnson
Performance & Momentum
J&J boosted by oncology, immunology wins
Johnson & Johnson is benefiting from several positive developments across its drug portfolio. The EMA has approved Darzalex for self-administration across ten oncology indications, a move that could strengthen the treatment’s penetration for multiple myeloma in Europe. In addition, the FDA has approved ICOTYDE for psoriasis, while a clinical agreement with GI Innovation further supports pipeline visibility. These announcements come as J&J seeks to offset pressure from declining Stelara sales and biosimilar competition. The stronger innovative portfolio and broader use of its therapies are generally positive for the stock, with a potentially supportive impact on near-term growth and investor sentiment.
Strategic Analysis
Johnson & Johnson • 2026
Johnson & Johnson relies on a diversified model that combines pharmaceutical innovations with advanced medical technologies. Its strength lies in its positioning in high-value segments such as oncology, cardiology, and surgery, with a renewed focus on anticipated segment growth for 2026.
Strengths
- Innovative portfolio covering key and growing therapeutic areas
- Strong global presence with a history of recognized innovations
- Ability to capitalize on diversification between pharmaceuticals and medical technologies
Weaknesses
- Facing operational and regulatory challenges in a competitive environment
Momentum
The momentum for Johnson & Johnson is positive, confirmed by sustained dynamics in recent months. The announced strategy of fostering segment growth demonstrates a willingness to proactively adapt to challenges, which could support average long-term performance.
Similar stocks to Johnson & Johnson
Recent News
Johnson & Johnson
Johnson & Johnson inks deal to cut drug prices
2 months agoJohnson & Johnson announced a voluntary agreement with the Trump administration to lower the prices of its drugs in the U.S. In exchange, the company's pharmaceutical products will receive tariff exemptions. This initiative aims to improve treatment access for millions of Americans while preserving J&J’s investments in innovation and local manufacturing. The deal could strengthen J&J's market position amid pricing pressures and positively impact investor sentiment.
Johnson & Johnson Bets on Segment Growth Amid Challenges
3 months agoJohnson & Johnson (JNJ) faces multiple headwinds in 2026, including the loss of Stelara patent protection, changes in Medicare reimbursement, talc-related lawsuits, and pressures on its medical sector in China. However, the company is relying on new product launches to drive division growth. This strategy will be crucial in offsetting negative impacts and maintaining investor confidence, especially as dividend growth appears favorable for 2026.
Johnson & Johnson Touted by Scotiabank as Cure Leader
4 months agoScotiabank recently selected Johnson & Johnson (NYSE: JNJ) as its top pick among ten major biopharma firms, highlighting an optimistic outlook on the sector. After years of lagging behind other industries, Johnson & Johnson is now gaining increased recognition for its prospects in curative treatments. This could boost investor interest and support the stock price on the NYSE. The recommendation strengthens the company's credibility in the fast-evolving healthcare market.
J&J Confirms Sustained 2-Year Remission in Crohn's Disease
5 months agoJohnson & Johnson reports encouraging Phase 3 data for Tremfya, showing sustained remission at 96 weeks in Crohn's disease. This therapeutic progress may strengthen JNJ's position in immunology, though market reaction remains stable with a modest daily fluctuation of -0.36%.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
